Stoke Therapeutics, Inc.
Stoke Therapeutics, Inc., a pioneering biotechnology company headquartered in the United States, focuses on developing innovative RNA-based therapies for severe genetic diseases. Founded in 2018, Stoke has quickly established itself in the biopharmaceutical industry, particularly in the field of genetic medicine. The company is renowned for its proprietary TANGO™ platform, which uniquely enhances the expression of specific genes to address the underlying causes of diseases. This cutting-edge approach sets Stoke apart in a competitive market, positioning it as a leader in the development of treatments for conditions such as epilepsy and other neurological disorders. With a commitment to advancing genetic therapies, Stoke Therapeutics continues to achieve significant milestones, solidifying its reputation as a key player in the biotechnology landscape.
DitchCarbon Score
How does Stoke Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Stoke Therapeutics, Inc.'s score of 20 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Stoke Therapeutics, Inc.'s reported carbon emissions
Stoke Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data or specific reduction targets. Without reported emissions figures, it is challenging to assess their carbon footprint or climate commitments in detail. However, the absence of data may indicate that the company is in the early stages of developing its sustainability strategy or reporting framework. In the broader context of the biotechnology industry, many companies are increasingly recognising the importance of addressing climate change and are setting ambitious targets to reduce their carbon emissions. Stakeholders often expect firms to adopt science-based targets and engage in initiatives that align with global climate goals. As Stoke Therapeutics progresses in its sustainability efforts, it may consider establishing measurable targets and reporting its emissions to enhance transparency and accountability in its climate commitments.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Stoke Therapeutics, Inc. is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
